Overview
ActivX Biosciences figures that the more you know about protein kinases, the easier it will be to inhibit them. That's the basis of its main product: a platform to profile protein kinases -- enzymes that regulate cells' signaling pathways. Its KiNativ platform has been launched for use by pharmaceutical and biotechnology companies as they develop the kinase inhibitors expected to make drug breakthroughs. The company also has its own pipeline of
...
Read More drug candidates in development, including one in trials for the treatment of Type-2 diabetes. Japanese drugmaker Kyorin Pharmaceutical, with whom ActivX had collaborated since 2002, bought the company in 2005 for $21 million.
Read Less
Read More drug candidates in development, including one in trials for the treatment of Type-2 diabetes. Japanese drugmaker Kyorin Pharmaceutical, with whom ActivX had collaborated since 2002, bought the company in 2005 for $21 million.
Read Less
John Kozarich
See more contacts
Scientific Research and Development Services
,
Professional, Scientific, and Technical Services
,
Biotechnical research, commercial
Accounting, Tax Preparation, Bookkeeping, and Payroll Services
,
Advertising, Public Relations, and Related Services
,
Architectural, Engineering, and Related Services
,
Computer Systems Design and Related Services
,
Legal Services
,
Management, Scientific, and Technical Consulting Services
,
Other Professional, Scientific, and Technical Services
,
Specialized Design Services
?
?
?
Actual
?
Actual
#
Modelled
?
?
Contacts
Get in Touch with 3 Principals* and 19 Contacts
-
John KozarichPresident
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Data
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.